Virus Production Platform
Multi-Virus Production Capability
Lentivirus, retrovirus, AAV, adenovirus, and oncolytic viruses.
Optimized High-Yield Processes
Customized upstream and purification workflows for each vector type.
GMP-Grade Quality Control
Full QC from raw materials to final release, meeting global standards.
High-Titer Outputs
Lentivirus titers up to 109 TU/mL for efficient gene delivery.
Enhanced Safety Design
Vector genome optimization and stringent biosafety protocols.
Advanced Automated Equipment
High-precision systems ensuring consistency, scalability, and cost efficiency.
Comprehensive Technology & Quality Control
Each virus is produced with tailored, high-yield processes — from optimized culture conditions and transfection strategies to precise purification protocols. A robust QC system spans raw material, inspection, in-process monitoring, and final release testing, including titer measurement, purity assessment, functional validation, and sterility checks, ensuring products meet international regulatory standards.
High Yield, High Purity, High Safety
Our platform consistently delivers high-titer vectors (e.g., lentivirus up to 109 TU/mL) with superior transduction efficiency and minimal impurities, reducing treatment cost and risk. Safety is ensured through vector genome design, removal of unnecessary genetic elements, and rigorous biosafety procedures.
Advanced Infrastructure
Critical production steps utilize imported, high-precision, automated equipment for consistent, reproducible results. This integration of advanced technology and strict quality management accelerates the commercialization of cell and gene therapies, enabling reliable, cost-effective vector supply for both clinical trials and large-scale manufacturing.
